Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab After R-CHOP Debulking Therapy for Richter Transformation
NCT03931642Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Jul 2019
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in Richter syndrome (RS), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Complete Remission Rate at 16 weeks. Started Jul 2019; status: completed.
02
Drugs
blinatumomab
03
Conditions
Richter syndrome (RS)
Beyond the preview
Go deeper on NCT03931642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03931642.